The first results of phase 3 of the vaccine from the Anglo-Swedish laboratory AstraZeneca and the British University of Oxford show that it has an average efficacy of 70.4%, as reported on Monday. Researchers have noted that “it is effective in preventing many people from getting sick and has been shown to work well in different age groups.”
Pfizer and Moderna have announced in recent weeks that the efficacy of their vaccines, based on preliminary results, is 95%. The British option is cheaper and easier to keep, versus the need to keep at exceptionally low temperatures the vaccine created by Pfizer and BioNTech (between -70 ºC and -80 ºC) and Moderna (-20 ºC). In the case of Oxford, it can be stored at 2-8ºC.RELATED
More than 20,000 volunteers – half in the United Kingdom and the rest in Brazil – have participated in the third phase of the clinical trials organized by the University of Oxford, which already gave good safety results in the second phase. In the last experiment, there were 131 positives: 30 cases in people who had received two doses of this antidote and 101 in the control group who received a harmless injection. The efficacy of the vaccine rose to 90% in a group of volunteers who were given a half initial dose followed by a full dose. They have not recorded serious cases or hospitalizations among people who received the vaccine, according to the Oxford statement.
On November 19, researchers reported that the second phase of clinical testing demonstrated that their vaccine is safe, with few side effects, in healthy people even over 70 years of age and elicits an immune response in all age groups, both with a low dose as standard.
Sarah Gilbert, a professor of vaccinology at Oxford and head of the project, said that the announcement “brings us one step closer to the moment when we can use vaccines to end the devastation caused by COVID-19.” “We will continue to work with regulators (who must authorize the vaccine). It has been a privilege to be part of a multinational effort that will reap benefits for everyone,” he said.
The ChAdOx1 nCoV-19 vaccine consists of viruses that affect chimpanzees and have been modified to resemble SARS-CoV-2. When this vaccine is inoculated, the immune system reacts as if it were the coronavirus. That of Pfizer and Moderna are developed with the technology known as messenger RNA or mRNA, which consists of “the production of the Spike (S) protein of the SARS-CoV-2 virus (it is part of the” spikes “of the coronavirus) through of RNA in the cells of the human body “.